Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health
Bethesda, United States
Mark Gilbert, MD is a Senior Investigator and Chief of the Neuro-Oncology Branch which is housed within in the Center for Cancer Research in the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland. Dr. Gilbert has focused his career and clinical and translational research ranging from preclinical analysis of new therapies to clinical trials including phase 0, phase I, phase II and phase III studies. This latter group includes two of the largeest clinical trials in the field, RTOG 0525 which tested the potential efficacy of dose-dense temozolomide in newly diagnosed glioblastoma and RTOG 0825 which examined the efficacy of bevacizumab in newly diagnosed glioblastoma. Complimenting his work in malignant gliomas, has been a long-standing interest in rare cancers of the nervous system. Starting with a leadership role in the Collaborative Ependymoma Research Network that has culminated in the successful application to the Beau Biden Cancer Moonshot for funding to set up and co-lead with Dr. Terri Armstrong, the national NCI-CONNECT program for rare CNS cancers. In addition, Dr. Gilbert leads a laboratory program that is exploring the next generation of precision medicine approaches to CNS cancers as well as a translational immunology program designed to better understand and overcome the limitations of these therapies for patients with brain and spinal cord cancers.